• Policy
• Countdown to initial non-face-to-face treatment
• by Lee, Jeong-Hwan Apr 5, 2023 05:48am

• Product
• Prescription of flu Txs rise with the spread of influenza A
• by Kang, Hye-Kyung Apr 5, 2023 05:48am

• Product
• No. of Paxlovid prescriptions drop at pharmacies
• by Jung, Heung-Jun Apr 5, 2023 05:47am

• Company
• Active M&A for global cell and gene therapy
• by Hwang, Jin-joon Apr 5, 2023 05:47am

• Company
• Celltrion discloses interim results of global phase 3 Eylea
• by Hwang, Jin-joon Apr 5, 2023 05:45am

• Company
• CHMP gave a positive opinion on the approval of Soliris
• by Jung, Sae-Im Apr 5, 2023 05:44am

• Company
• Hanmi internationally introduces 7 new drug candidates
• by Hwang, Jin-joon Apr 4, 2023 05:53am

• Company
• Medytox paid service fees of KRW 97.7B in 4 years
• by Kim, Jin-Gu Apr 4, 2023 05:52am

• Company
• Pharma companies face the crisis ‘head-on'
• by Chon, Seung-Hyun Apr 3, 2023 05:49am

• Company
• Hugel appoints Seok-yong Cha, former CEO
• by Lee, Seok-Jun Apr 3, 2023 05:49am